Drug Approval | December 06, 2024
FDA accepts supplemental Biologics License Application for Roche’s Columvi combination
For people with relapsed or refractory diffuse large B-cell lymphoma
For people with relapsed or refractory diffuse large B-cell lymphoma
Launch of new product range aligns with strategy to diversify into emerging applications with high growth potential
Emcure will play a crucial role in ensuring the availability of high-quality, low-cost versions of lenacapavir in 120 countries
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
The inspection conducted by EDQM at its Visakhapatnam facility
NUBEQA is currently indicated for the treatment of adult patients with mHSPC in combination with docetaxel and for non-metastatic castration-resistant prostate cancer (nmCRPC)
Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression
Both the products are Gadolinium based Magnetic Resonance Imaging (MRI) contrast agents and will be the first set of contrast agent products in Zydus’ injectable portfolio for the US market
Birajeev is a seasoned Supply Chain leader with an experience of 23 years
This partnership aims to accelerate research and development into innovative treatments and, if successful, will generate milestones and royalties
Subscribe To Our Newsletter & Stay Updated
